Stock Market Reviews

Read and share opinions on ATOS (Atossa Therapeutics, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock marke

Latest News

• Atossa Therapeutics Wins 2025 Clinical Trials Arena Research and Development Excellence Award in Precision Endocrine Therapy Category
  Dec 17, 2025
• Atossa Therapeutics Presents Four Clinical Trial Updates Highlighting (Z)-Endoxifen Research at the 2025 San Antonio Breast Cancer Symposium
  Dec 15, 2025
• Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for Duchenne Muscular Dystrophy
  Dec 11, 2025
• Atossa Therapeutics Announces Issuance of U.S. Patent Covering Enteric Oral (Z)-Endoxifen Formulations and Methods of Treating Patients Using (Z)-Endoxifen
  Dec 9, 2025
• Atossa Therapeutics Details Accelerated FDA Strategy to Advance (Z)-Endoxifen Across Breast Cancer Continuum
  Dec 4, 2025
• Insilico Medicine and Atossa Therapeutics Publish AI-Driven Study in Nature Scientific Reports Identifying (Z)-Endoxifen as a Potential Therapeutic Candidate for Glioblastoma
  Dec 2, 2025
• Atossa Highlights Emerging Opportunity for (Z)-Endoxifen in Duchenne Muscular Dystrophy, Including Symptomatic Female Carriers, Following Peer-Reviewed Publication and Scientific Presentation
  Nov 17, 2025
• Atossa Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
  Nov 12, 2025
• Atossa Therapeutics Announces Acceptance of Four Abstracts Highlighting (Z)-Endoxifen Research for Presentation at the 2025 San Antonio Breast Cancer Symposium
  Nov 6, 2025
• New Strong Sell Stocks for Oct. 22
  Oct 22, 2025
• Atossa Therapeutics Highlights Progress in RECAST™ DCIS Platform Trial at Early Detection Research Conference; Laura Esserman, MD, MBA, to Discuss Active-Surveillance Strategy and Novel Endocrine Agents
  Oct 21, 2025
• Atossa Therapeutics to Present at the Maxim Growth Summit 2025
  Oct 15, 2025
• Atossa Appoints Mark Daniel, CPA, as Chief Financial Officer to Lead Finance, Systems, and Capital Strategy for Commercial Readiness
  Oct 14, 2025
• Atossa Advances Global Patent Strategy for Z-Endoxifen with New Protection in Israel and Ongoing Renewals
  Oct 13, 2025
• Atossa Therapeutics Streamlines EVANGELINE Breast Cancer Clinical Trial to Prioritize for 2026 NDA-Enabling Activities
  Oct 6, 2025
• Atossa Therapeutics Names Janet R. Rea, MSPH, as Senior Vice President, R&D to Accelerate (Z)-Endoxifen Toward Key Regulatory Milestones
  Oct 1, 2025
• Atossa Therapeutics Appoints CORE IR for Investor Relations, Shareholder Communications and Public Relations Services
  Sep 17, 2025
• Atossa Therapeutics Announces Regulatory Strategy Aimed at Accelerating Development of Low-Dose (Z)-Endoxifen for Breast Cancer Risk Reduction
  Sep 8, 2025
• NioCorp and Atossa Therapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
  Aug 29, 2025

ATOS News

• Atossa Therapeutics Wins 2025 Clinical Trials Arena Research and Development Excellence Award in Precision Endocrine Therapy Category
  Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, announces that it has been selected as a winner of the 2025 Clinical Trials Arena Excellence Awards. The Company was honored with the Research and Development Award in the Precision Endocrine Therapy category.
  Dec 17, 2025
• Atossa Therapeutics Presents Four Clinical Trial Updates Highlighting (Z)-Endoxifen Research at the 2025 San Antonio Breast Cancer Symposium
  Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines in oncology and other areas of high unmet need, presented four clinical trial updates on (Z)-endoxifen at the San Antonio Breast Cancer Symposium (SABCS), held December 9-12, 2025, in San Antonio, TX.
  Dec 15, 2025
• Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for Duchenne Muscular Dystrophy
  Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announced that the U.S. Food and Drug Administration ("FDA") has granted Rare Pediatric Disease ("RPD") designation to (Z)-Endoxifen for the treatment of Duchenne Muscular Dystrophy ("DMD").
  Dec 11, 2025
• Atossa Therapeutics Announces Issuance of U.S. Patent Covering Enteric Oral (Z)-Endoxifen Formulations and Methods of Treating Patients Using (Z)-Endoxifen
  Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative therapies in areas of significant unmet need in breast cancer, today announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 12,479,790 B2, titled, "Methods for Making and Using Endoxifen."
  Dec 9, 2025
• Atossa Therapeutics Details Accelerated FDA Strategy to Advance (Z)-Endoxifen Across Breast Cancer Continuum
  Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company focused on transforming breast cancer treatment and prevention, announced the completion of a Type C meeting with the U.S. Food and Drug Administration ("FDA") on November 17, 2025, to review regulatory strategy for advancing (Z)-endoxifen. During the meeting, the FDA provided the Company feedback on potential expedited regulatory pathways and development options across metastatic dis
  Dec 4, 2025
• Insilico Medicine and Atossa Therapeutics Publish AI-Driven Study in Nature Scientific Reports Identifying (Z)-Endoxifen as a Potential Therapeutic Candidate for Glioblastoma
  Insilico Medicine ("Insilico"), a global leader in AI-powered drug discovery, and Atossa Therapeutics ("Atossa") (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel treatments for breast cancer and other serious conditions, announce the publication of a joint study evaluating the potential of (Z)-endoxifen for glioblastoma multiforme (GBM). The peer-reviewed article, now published in Nature's Scientific Reports, represents one of the most comprehensive AI-enabled analyses
  Dec 2, 2025
• Atossa Highlights Emerging Opportunity for (Z)-Endoxifen in Duchenne Muscular Dystrophy, Including Symptomatic Female Carriers, Following Peer-Reviewed Publication and Scientific Presentation
  Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines in oncology, announces a growing body of scientific work supporting the potential role of its investigational therapy (Z)-endoxifen in DMD, a severe, progressive, and ultimately fatal neuromuscular disease, in addition to Duchenne carrier–associated pathologies (D-CAPs) that affect a subset of female carriers. The momentum is anchored by a newly publish
  Nov 17, 2025
• Atossa Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
  Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing proprietary innovative medicines in areas of significant unmet medical need in oncology, today announces its financial results for the third quarter ended September 30, 2025 and provides an update on recent corporate developments.
  Nov 12, 2025
• Atossa Therapeutics Announces Acceptance of Four Abstracts Highlighting (Z)-Endoxifen Research for Presentation at the 2025 San Antonio Breast Cancer Symposium
  Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines in oncology, announces that four abstracts featuring data on (Z)-endoxifen have been accepted for presentation at the San Antonio Breast Cancer Symposium (SABCS), being held on December 9-12, 2025, in San Antonio, TX.
  Nov 6, 2025
• New Strong Sell Stocks for Oct. 22
  ATOS, BLIN and CLTP have been added to the Zacks Rank #5 (Strong Sell) List on Oct. 22, 2025.
  Oct 22, 2025
• Atossa Therapeutics Highlights Progress in RECAST™ DCIS Platform Trial at Early Detection Research Conference; Laura Esserman, MD, MBA, to Discuss Active-Surveillance Strategy and Novel Endocrine Agents
  Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines in oncology, today announced that Laura J. Esserman, MD, MBA, Professor of Surgery and Radiology at the University of California, San Francisco and Principal Investigator of RECAST™, will speak at the Early Detection Research Conference in Portland, OR, about the Company's collaborative work in the RECAST platform trial for ductal carcinoma in situ (DCI
  Oct 21, 2025
• Atossa Therapeutics to Present at the Maxim Growth Summit 2025
  Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing new approaches in breast cancer treatment and prevention, announces that Chairman and Chief Executive Officer Steven Quay, M.D., Ph.D. will participate in the Maxim Growth Summit on October 22–23, 2025 at the Hard Rock Hotel, New York City. Dr. Quay will also be available for one-on-one investor meetings during the conference.
  Oct 15, 2025
• Atossa Appoints Mark Daniel, CPA, as Chief Financial Officer to Lead Finance, Systems, and Capital Strategy for Commercial Readiness
  Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing new approaches in breast cancer treatment and prevention, announces the appointment of Mark Daniel, CPA (WA; inactive), as Chief Financial Officer. Mr. Daniel is a senior finance leader with more than 25 years of experience building the forecasting cadence, systems, and public-company discipline that support revenue scale in global life-science businesses. He has overseen w
  Oct 14, 2025
• Atossa Advances Global Patent Strategy for Z-Endoxifen with New Protection in Israel and Ongoing Renewals
  Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing new approaches in breast cancer treatment and prevention, announces key progress in its global intellectual-property strategy for Z-endoxifen, including the issuance of an Israeli patent and continued renewals that reinforce protection for the Company's lead program across major jurisdictions. The Israeli patent (No. 304863), titled, "Methods for Making and Using Endoxifen,
  Oct 13, 2025
• Atossa Therapeutics Streamlines EVANGELINE Breast Cancer Clinical Trial to Prioritize for 2026 NDA-Enabling Activities
  Atossa Therapeutics, Inc. (Nasdaq: ATOS; "Atossa" or the "Company), a clinical-stage biopharmaceutical company developing new approaches in breast cancer treatment and prevention, announces an amendment to its Phase 2 EVANGELINE study of (Z)-endoxifen in premenopausal women with newly diagnosed early-stage ER+/HER2- breast cancer. The amended, non-registrational design is expected to accelerate objective readouts while reducing projected future study costs, consistent with Atossa's focus on exte
  Oct 6, 2025
• Atossa Therapeutics Names Janet R. Rea, MSPH, as Senior Vice President, R&D to Accelerate (Z)-Endoxifen Toward Key Regulatory Milestones
  Atossa Therapeutics, Inc. (Nasdaq: ATOS; "Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing new approaches in breast cancer treatment and prevention, announces the appointment of Janet R. Rea, MSPH to its newly created position Senior Vice President, R&D. Ms. Rea brings more than two decades of strategic research and clinical development expertise, with a success record for regulatory approvals, to oversee late-stage (Z)-endoxifen programs with near term priorities
  Oct 1, 2025
• Atossa Therapeutics Appoints CORE IR for Investor Relations, Shareholder Communications and Public Relations Services
  Engagement to enhance investor awareness, strengthen shareholder engagement, and broaden reach to target institutional and retail audiencesSEATTLE, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS; “Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing new approaches in breast cancer treatment and prevention, today announces it has appointed CORE IR, a strategic investor relations, public relations, and corporate advisory firm, to support the
  Sep 17, 2025
• Atossa Therapeutics Announces Regulatory Strategy Aimed at Accelerating Development of Low-Dose (Z)-Endoxifen for Breast Cancer Risk Reduction
  Atossa Therapeutics, Inc. (Nasdaq: ATOS; "Atossa" or the "Company") announced today it has requested a Type C meeting with the U.S. Food and Drug Administration (FDA) to discuss a regulatory strategy aimed at accelerating development of low-dose (Z)-endoxifen for breast cancer risk reduction. Atossa is a clinical-stage biopharmaceutical company developing new approaches in breast cancer treatment and risk-reduction, commonly termed prevention of breast cancer.
  Sep 8, 2025
• We're Hopeful That Atossa Therapeutics (NASDAQ:ATOS) Will Use Its Cash Wisely
  There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
  Sep 2, 2025
• NioCorp and Atossa Therapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
  ORLANDO, FL / ACCESS Newswire / August 29, 2025 / RedChip Companies will air interviews with NioCorp Developments Ltd. (Nasdaq:NB) and Atossa Therapeutics, Inc. (Nasdaq:ATOS) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg ...
  Aug 29, 2025
• Atossa Therapeutics CEO to Discuss Clinical Progress and Upcoming Milestones at 27th Annual H.C. Wainwright Global Investment Conference
  Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing new approaches in breast cancer treatment and prevention, today announced that Dr. Steven Quay, Chairman and Chief Executive Officer, will participate in a fireside chat with biotech research analyst, Emily Bodnar, at the H.C. Wainwright (HCW) 27th Annual Global Investment Conference on Monday, September 8, 2025, at 3:00 p.m. ET, at the Lotte New York Palace Hotel in New Yo
  Aug 28, 2025
• Atossa Therapeutics Selects PSI as Contract Research Organization for Pivotal Dose-Ranging Study of (Z)-Endoxifen in Metastatic Breast Cancer
  Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, announced today it has selected PSI, a leading global contract research organization (CRO), to operationalize and manage its planned (Z)-endoxifen monotherapy dose-ranging study in women with metastatic breast cancer (mBC). The study was designed following guidance from the U.S. Food and Drug Administration (FDA) and is intended to di
  Aug 20, 2025
• Atossa Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Corporate Update
  Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced its financial results for the second quarter ended June 30, 2025 and provided an update on recent company developments.
  Aug 12, 2025
• Atossa Therapeutics and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
  ORLANDO, FL / ACCESS Newswire / August 1, 2025 / RedChip Companies will air interviews with Calidi Biotherapeutics, Inc. (NYSE American:CLDI) and Atossa Therapeutics, Inc. (Nasdaq:ATOS) on the RedChip Small Stocks, Big Money™ show, a sponsored program ...
  Aug 1, 2025
• Atossa Therapeutics Announces Positive FDA Feedback, Advances Toward IND for (Z)-Endoxifen Clinical Program in ER+/HER2- Metastatic Breast Cancer
  Atossa Therapeutics, Inc. (NASDAQ: ATOS), a clinical-stage biopharmaceutical company developing innovative medicines in oncology, today announced positive written feedback from the U.S. Food and Drug Administration (FDA) regarding the company's proposed dose optimization trial of (Z)-endoxifen for the treatment of estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer.
  Jul 29, 2025
• Ascendiant Lifts Atossa Therapeutics, Inc. (ATOS) Target Citing Strong Liquidity
  Atossa Therapeutics, Inc. (NASDAQ:ATOS) is among the best growth stocks to invest in for the next 5 years. Ascendiant Capital analysts slightly increased the price target for Atossa Therapeutics, Inc. (NASDAQ:ATOS) to $7.50, up from $7.25, with an unchanged Buy rating. This potential surge of 837% from current levels reinforces the company’s attractive valuation. In […]
  Jul 3, 2025

ATOS Reviews

• OptionOverlord

  Dec 30, 2025

  $ATOS They’re chasing big dreams, but I hope they don’t trip over their own shoelaces! 👟

  Sell

• TickerPhantom

  Dec 30, 2025

  $ATOS Engaged in advancing healthcare solutions, this firm is focusing on significant unmet medical needs. Its pipeline of innovative therapies could provide substantial value, especially as it navigates regulatory milestones.

  Buy

• MoneyMage

  Dec 30, 2025

  $ATOS This company feels like it's allergic to success.

  Sell

• TradeProtocol

  Dec 28, 2025

  $ATOS This stock dives into the health scene, hoping to be a lifesaver! But let’s hope it doesn't take too many trips underwater!

  Sell

• GammaSlayer

  Dec 27, 2025

  $ATOS A real winner if you like watching paint dry.

  Sell

• BearishBoi

  Dec 27, 2025

  $ATOS This company's got the kind of vibe that makes you want to wear a lab coat and start mixing potions. Science, here we come!

  Sell

• BearHunter

  Dec 24, 2025

  $ATOS If this company were a superhero, it’d be all about saving the day—just without the cape and the spandex!

  Buy

• WallStreetWolf

  Dec 24, 2025

  $ATOS Their name sounds like a superhero, but their mission is to tackle some serious health challenges. Capes optional!

  Buy

• MissionOverlord

  Dec 22, 2025

  $ATOS Things are looking a bit shaky here, might wanna tread lightly.

  Sell

• YOLOTrader69

  Dec 22, 2025

  $ATOS Watch out for this one, it’s got some wild potential brewing!

  Buy

• VolatilityStrike

  Dec 21, 2025

  $ATOS With a commitment to advancing healthcare through innovative therapies, this firm is at the forefront of transforming treatment options for patients, showcasing significant potential for growth.

  Buy

• RiskReaper

  Dec 21, 2025

  $ATOS This company is making strides in innovative therapeutics, addressing significant unmet medical needs. Their commitment to research and development positions them well within the healthcare sector, attracting interest from both investors and healthcare professionals.

  Buy

• MarketMatrix

  Dec 21, 2025

  $ATOS Finding a cure sounds great, but remember, even superheroes need a day off—don’t forget to relax, folks!

  Sell

• WallStreetHex

  Dec 21, 2025

  $ATOS With a pipeline that addresses pressing health concerns, this organization has the potential to significantly impact the treatment landscape for various serious conditions.

  Buy

• ShortSniper

  Dec 21, 2025

  $ATOS Pushing unproven treatments like a garage inventor.

  Sell

• LiquidLegend

  Dec 21, 2025

  $ATOS Trying to cure what ails you? Sounds like they're the trusted friend who brings snacks to a study session—totally essential!

  Buy

• AlphaRogue

  Dec 20, 2025

  $ATOS Think of this one as the underdog superhero—tough on the outside, but could totally save the day if given the chance! 🦸‍♂️

  Buy

• TradePredator

  Dec 20, 2025

  $ATOS Hope you like waiting, because this is a marathon.

  Sell

• PixelBroker

  Dec 19, 2025

  $ATOS This stock is like a science experiment gone right – it’s all about breakthroughs that could make you go ‘whoa!’

  Sell

• ShortAndProud

  Dec 19, 2025

  $ATOS Breaking barriers in health, they're on the cutting edge!

  Buy

• DiamondHandz

  Dec 18, 2025

  $ATOS This one’s got the hustle; could make waves in the game!

  Buy

• ProfitLancer

  Dec 18, 2025

  $ATOS This one's a sinking ship; hope you can swim.

  Sell

• AlgoAce

  Dec 17, 2025

  $ATOS This biotech is working on breakthroughs that could make you say 'who needs a time machine' when you can just heal faster?

  Buy

• CapitalVortex

  Dec 17, 2025

  $ATOS The latest trial results are sending waves through the market—investors are holding their breath, waiting for the breakthrough or a total flop! This one's riding the edge of excitement and despair!

  Buy

• MoneyMage

  Dec 16, 2025

  $ATOS A therapeutics company without any real therapy.

  Sell

• VolatilityNomad

  Dec 15, 2025

  $ATOS This one's got more twists than a soap opera, and not in a good way.

  Sell

• AlphaDecoder

  Dec 15, 2025

  $ATOS Focused on therapeutic innovations, this company is addressing pressing health needs with its unique offerings. Its emphasis on research and development may lead to breakthroughs that capture market interest.

  Buy

• LiquidLegend

  Dec 15, 2025

  $ATOS If this stock was a dessert, it’d be a mystery flavor – exciting at first, but you might regret it later!

  Sell

• PixelBroker

  Dec 15, 2025

  $ATOS Talk about a plot twist! This company leaves us guessing like a Netflix series cliffhanger. What’s next?

  Sell

• IndexPredator

  Dec 15, 2025

  $ATOS This biotech is navigating a stormy sea of clinical trials and market skepticism. Can they steer through the chaos and emerge as a leader in their field?

  Buy

• YOLOHold

  Dec 14, 2025

  $ATOS Seems like a wild ride, could be a risky gamble!

  Sell

• BagholderElite

  Dec 14, 2025

  $ATOS This one’s got potential, might surprise the haters!

  Buy

• RiskProtocol

  Dec 13, 2025

  $ATOS This company is navigating a turbulent landscape with groundbreaking treatments that could change everything. The potential is sky-high, but can they handle the pressure? It's a tightrope walk that keeps investors on their toes.

  Buy

• TradePulse

  Dec 13, 2025

  $ATOS Short-term structure collapsing.

  Sell

• AlphaVandal

  Dec 13, 2025

  $ATOS Downside pressure unrelenting.

  Sell

• WallStreetWraith

  Dec 12, 2025

  $ATOS Bearish pressure accelerating quickly.

  Sell

• MarketDrift

  Dec 12, 2025

  $ATOS They’re pushing boundaries, might just be the comeback kid, ya dig?

  Buy

• ShortSavage

  Dec 12, 2025

  $ATOS Uptrend continuing flawlessly.

  Buy

• TradeGoblin

  Dec 11, 2025

  $ATOS Feels like a gamble, but sometimes high risks mean big rewards.

  Sell

• FUDCrusher

  Dec 11, 2025

  $ATOS Buyers absorbing sell orders effortlessly.

  Buy

• QuantRift

  Dec 11, 2025

  $ATOS With a focus on developing cutting-edge therapeutics, this biopharmaceutical company is navigating a dynamic landscape with potential breakthroughs on the horizon. Its pipeline could be an exciting prospect for those interested in healthcare innovation.

  Buy

• TheMemeInvestor

  Dec 11, 2025

  $ATOS Innovations are poppin', but is the hype real? Keep your eyes peeled.

  Sell

• RiskReaper

  Dec 11, 2025

  $ATOS Bullish breakout imminent.

  Buy

• OptionNomad

  Dec 11, 2025

  $ATOS Falling knife scenario forming.

  Sell

• ShortSniper

  Dec 11, 2025

  $ATOS Momentum strongly bearish.

  Sell

• TheGainReaper

  Dec 10, 2025

  $ATOS Yet another 'breakthrough' that’s all hype.

  Sell

• CodeAndCapital

  Dec 10, 2025

  $ATOS This stock is like that friend who never quits—always trying to turn the tide, one sleepless night at a time!

  Sell

• TheTradingVerse

  Dec 10, 2025

  $ATOS This organization is at the forefront of developing breakthrough therapies, addressing significant unmet medical needs. Its innovative pipeline and strategic partnerships may provide substantial opportunities for advancement in the healthcare sector.

  Buy

• CandleKnight

  Dec 10, 2025

  $ATOS Bringing innovation to the game, watch out for this player’s next move!

  Buy

• GammaSlayer

  Dec 10, 2025

  $ATOS You're still waiting for this one to take off?

  Sell

• OptionRogue

  Dec 9, 2025

  $ATOS This organization is engaged in the biopharmaceutical space, focusing on treatments for serious medical conditions. Their dedication to advancing innovative therapies positions them as a potential opportunity in the healthcare market.

  Buy

• DividendVortex

  Dec 9, 2025

  $ATOS This company is making strides in the biopharmaceutical sector, showcasing innovative approaches that could potentially transform treatment options. Their focus on developing therapies that target unmet medical needs reflects a commitment to advancement in healthcare.

  Buy

• BullishCraze

  Dec 9, 2025

  $ATOS In the biotech industry, this organization is focused on developing cutting-edge therapies that address critical health needs. Their ongoing research initiatives indicate a forward-looking approach, aligning well with emerging healthcare demands.

  Buy

• TradePulse

  Dec 9, 2025

  $ATOS Powerful continuation setup.

  Buy

• CodeAndCapital

  Dec 9, 2025

  $ATOS Support zones failing fast.

  Sell

• BullishBard

  Dec 9, 2025

  $ATOS This therapeutic journey seems like a rollercoaster ride at an amusement park. Buckle up for some wild ups and downs!

  Sell

• MarginMeme

  Dec 8, 2025

  $ATOS This one's got potential, keep your eyes peeled, fam.

  Buy

• FinTechFrost

  Dec 8, 2025

  $ATOS This one’s diving into therapies like it's going for a cannonball at the pool—splashing and hoping for a perfect exit!

  Buy

• ProfitVortex

  Dec 7, 2025

  $ATOS This stock is like a bag of gummy bears – colorful, sweet, and occasionally gives you a sugar rush! Just don’t overdo it.

  Buy

• YieldMyth

  Dec 7, 2025

  $ATOS This joint's got potential like a hidden gem, keep an eye on it!

  Buy

• CashOverload

  Dec 7, 2025

  $ATOS More hype than substance; but hey, good luck!

  Sell

• ShortAndProud

  Dec 6, 2025

  $ATOS Short-term and long-term charts align bearish.

  Sell

• MarketGlitch

  Dec 6, 2025

  $ATOS With clinical trials hanging in the balance, this biotech's future feels like a high-stakes gamble. Investors are on edge waiting for the next pivotal announcement!

  Buy

• TheAlphaDagger

  Dec 5, 2025

  $ATOS With a focus on transforming health, can this company navigate the treacherous waters of regulation and competition? It's an uphill battle that has investors sweating!

  Buy

• BuyLowBro

  Dec 4, 2025

  $ATOS Turning the healthcare game upside down! Can’t wait till I can get a prescription with a side of fries!

  Sell

• MarketRender

  Dec 4, 2025

  $ATOS In the race for groundbreaking treatments, will this therapeutic entity find its stride or be lost in the shuffle? The tension is palpable as results loom!

  Sell

• RiskRaider

  Dec 4, 2025

  $ATOS Unstable price action pointing downward.

  Sell

• BuyLowBoi

  Dec 4, 2025

  $ATOS Struggling to gain traction, feels like they’re in the slow lane.

  Sell

• HoldTheLine

  Dec 4, 2025

  $ATOS This looks like a classic bull trap.

  Sell

• MarketSavage

  Dec 4, 2025

  $ATOS Lower timeframe collapse forming.

  Sell

• ShortSurge

  Dec 4, 2025

  $ATOS This company is making significant strides in developing innovative therapies, showcasing strong potential for future growth in a promising sector.

  Buy

• CashCombo

  Dec 4, 2025

  $ATOS If this stock were a superhero, it would be the one with the weird powers that actually work! Trust me, you’ll want them on your team.

  Buy

• PnLPhantom

  Dec 3, 2025

  $ATOS The healthcare sector is a relentless battlefield, and every drug trial feels like a do-or-die moment. You can't shake the tension that hangs in the air, waiting for the results!

  Sell

• ShortRaid

  Dec 3, 2025

  $ATOS Engaged in cutting-edge therapeutic developments, this company is dedicated to addressing critical health challenges. Its robust pipeline and commitment to patient-centric solutions suggest a promising trajectory in the biotech field.

  Buy

• WallStreetBandit

  Dec 3, 2025

  $ATOS This one’s got more problems than solutions; good luck with that.

  Sell

• CryptoCobra

  Dec 3, 2025

  $ATOS This stock feels like getting lost in a Netflix series—mysterious, kinda weird, but you can’t look away!

  Sell

• RiskReaper

  Dec 2, 2025

  $ATOS This biotechnology firm is engaged in developing novel treatments aimed at serious diseases. Their dedication to research could pave the way for significant advancements in patient health.

  Buy

• EquityPulse

  Dec 1, 2025

  $ATOS Things seem to be heating up here! There’s innovation brewing, but will they deliver when it counts? Buckle up for a wild ride as investors weigh in!

  Buy

• BearHunter

  Dec 1, 2025

  $ATOS This company is like a rollercoaster – thrilling ups and scary downs, but hey, who doesn’t love a little adrenaline?

  Sell

• ShortCircuit

  Nov 30, 2025

  $ATOS A rollercoaster ride, but the thrills are gone.

  Sell

• AlphaStriker

  Nov 30, 2025

  $ATOS Investing here feels like throwing good money after bad.

  Sell

• EarningsSync

  Nov 29, 2025

  $ATOS This one has potential in the biotech field, yet the race to successful therapies is fraught with obstacles. Can they navigate the storm?

  Sell

• CandleBinary

  Nov 29, 2025

  $ATOS This company is at the forefront of innovative advancements in healthcare, focusing on therapies that aim to address significant unmet medical needs. Their commitment to research and development positions them as a player to watch in the biopharmaceutical sector.

  Buy

• BullishVanguard

  Nov 29, 2025

  $ATOS Just another biotech hoping for a miracle that may never come.

  Sell

• ChartPhantom

  Nov 29, 2025

  $ATOS This company is like the superhero of healthcare! If you need a health upgrade, they're here to save the day faster than you can say 'metabolism'!

  Buy

• BearHunter

  Nov 28, 2025

  $ATOS When life gets tough, tough companies get going! This one’s on the road to recovery!

  Buy

• StonkKnight

  Nov 28, 2025

  $ATOS It’s a wild ride, but those swings can be tasty!

  Sell

• ShortAndProud

  Nov 28, 2025

  $ATOS They’re pushin’ boundaries in health, keep an eye on this crew!

  Buy

• TheGainReaper

  Nov 27, 2025

  $ATOS This feels like a perpetual waiting game for something miraculous.

  Sell

• MarginMyth

  Nov 26, 2025

  $ATOS Atossa? More like a total loss.

  Sell

• ShortKingston

  Nov 26, 2025

  $ATOS When your treatments are cutting edge, you might as well be wearing a lab coat made of the latest fashion trends!

  Sell

• BullishVanguard

  Nov 26, 2025

  $ATOS Waiting for this stock to shine is like waiting for a miracle.

  Sell

• MarketMyth

  Nov 26, 2025

  $ATOS This organization is dedicated to pioneering treatments that could reshape patient outcomes in the healthcare market. Its focus on groundbreaking research and development demonstrates a promising direction for future growth.

  Buy

• IndexPredator

  Nov 26, 2025

  $ATOS With constant fluctuations and mixed news swirling around, staying updated is crucial. The potential for breakthrough or disaster is palpable, leaving investors on the edge of their seats!

  Buy

• MarginMythic

  Nov 26, 2025

  $ATOS Pioneering new solutions, but at what cost? The intensity of the race could either propel them to the front or lead to a disheartening collapse. Time will tell!

  Buy

• ProfitVortex

  Nov 26, 2025

  $ATOS If this company were a superhero, it’d definitely have a cool backstory involving a lab accident and lots of caffeine!

  Buy

• BearFighter

  Nov 26, 2025

  $ATOS This one’s like a roller coaster, but the ride is broken.

  Sell

• EquityAssault

  Nov 26, 2025

  $ATOS A biotech gamble that feels more like a bad bet.

  Sell

• MarketRender

  Nov 26, 2025

  $ATOS The volatility around this company is enough to make anyone’s heart race! Innovation seems promising, but the market's reaction has been nothing short of frenetic. Can they keep up the momentum?

  Sell

• OptionNomad

  Nov 26, 2025

  $ATOS With innovation efforts ramping up, can this therapeutic company keep pace? The anticipation is nerve-wracking, and the clock is ticking!

  Sell

• YieldHunter

  Nov 25, 2025

  $ATOS With a strong focus on innovative therapies targeting critical health conditions, this firm is positioned at the forefront of biopharmaceutical advancements. Their pipeline showcases promising potential.

  Buy

• WallStreetGrim

  Nov 25, 2025

  $ATOS With groundbreaking research in therapeutics, this company is aiming to make significant strides in the healthcare arena. Its dedication to addressing unmet medical needs is commendable and reflects potential for impactful results.

  Buy

• DividendDegen

  Nov 24, 2025

  $ATOS Keep your eyes peeled, it’s got that underdog energy.

  Buy

• TheRiskDealer

  Nov 24, 2025

  $ATOS As the biotech sector faces mounting scrutiny and unpredictable trial outcomes, the pressure to produce results could turn this hopeful contender into an anxious gamble. The stakes are sky-high!

  Buy

• DividendJunkie

  Nov 24, 2025

  $ATOS Therapeutics? More like therapeutic losses.

  Sell

• TradeGoblin

  Nov 23, 2025

  $ATOS This one's riding a wild wave, gotta watch it closely.

  Sell

• MarketNomad

  Nov 22, 2025

  $ATOS This stock is a one-way ticket to disappointment.

  Sell

• ChartNomad

  Nov 22, 2025

  $ATOS Amidst fierce competition and market jitters, the stakes couldn’t be higher. Will this company seize the moment or get lost in the noise? Investors are anxiously waiting for clarity!

  Sell

• GammaGrind

  Nov 22, 2025

  $ATOS Yo, they’re heating up in biotech, don’t miss out!

  Buy

• DividendJunkie

  Nov 22, 2025

  $ATOS This company couldn't find its way out of a paper bag.

  Sell

• YieldMyth

  Nov 21, 2025

  $ATOS This one's got potential to shine bright, folks waiting for the next big move!

  Buy

• BagholderElite

  Nov 21, 2025

  $ATOS This one's got potential, keep an eye on it, fam!

  Buy

• MarketRender

  Nov 20, 2025

  $ATOS With promising developments in the pipeline, this firm is on the edge of a breakthrough. Yet, the pressure to deliver is immense! Can they turn potential into profit? Time is ticking!

  Buy

• TradePulse

  Nov 20, 2025

  $ATOS With recent fluctuations and a promising pipeline, the tension surrounding this stock is palpable! Investors are on edge, waiting for news that could either make or break the potential. Will it soar or plummet next week?

  Buy

• GainMachine

  Nov 20, 2025

  $ATOS In the world of therapeutics, this company is like the superhero—saving lives one treatment at a time, cape not included.

  Buy

• BearBreaker

  Nov 20, 2025

  $ATOS This one’s a rollercoaster, but the ride’s broken.

  Sell

• BearHunter

  Nov 19, 2025

  $ATOS This company is like a lab coat-wearing wizard, conjuring up breakthroughs in healthcare one potion at a time!

  Buy

• TradeProtocol

  Nov 17, 2025

  $ATOS This company’s got the health vibes! It’s like the gym of stocks—great potential but sometimes hard to keep up with!

  Sell

• LiquidityLord

  Nov 16, 2025

  $ATOS By focusing on pioneering therapies and fostering strategic collaborations, this organization is positioning itself at the forefront of medical innovation, which may resonate well with stakeholders.

  Buy

• ChartCrusher

  Nov 16, 2025

  $ATOS Chasing trends instead of focusing on real problems.

  Sell

• EquityPulse

  Nov 16, 2025

  $ATOS The health sector is a pressure cooker right now! Can this firm navigate the storm of clinical trials and regulatory hurdles without losing their footing?

  Sell

• CapitalVortex

  Nov 15, 2025

  $ATOS Every day feels like a race against time with this one; you never know when the next news will come crashing in like a tidal wave!

  Sell

• MarketRender

  Nov 15, 2025

  $ATOS With eyes on the latest treatment breakthroughs, the pressure is mounting! Will they deliver groundbreaking results or vanish into the shadows of missed expectations?

  Sell

• FiscalEngine

  Nov 15, 2025

  $ATOS Focusing on groundbreaking therapeutics, this company is pushing the boundaries of medical science. Its dedication to addressing unmet medical needs could yield significant breakthroughs in health care.

  Buy

• BullRunBoss

  Nov 15, 2025

  $ATOS Therapeutics that sound cooler than the latest superhero movie! Does this come with a cape?

  Buy

• HODLWarrior

  Nov 15, 2025

  $ATOS A wild card, but it’s buzzing like a party, keep an eye on it!

  Buy

• ShortSavage

  Nov 14, 2025

  $ATOS In the healthcare sector, the pressure is relentless. Will this company manage to break the mold and deliver groundbreaking results, or will its efforts fizzle out?

  Buy

• WallStreetBandit

  Nov 14, 2025

  $ATOS Another name trying desperately to stay relevant.

  Sell

• TradeReckoner

  Nov 14, 2025

  $ATOS A drug company focused on hope, not results.

  Sell

• ShortKingston

  Nov 14, 2025

  $ATOS They’re like that friend who always brings snacks to the party—everybody loves them, and they make everything better!

  Buy

• MarketMatrix

  Nov 12, 2025

  $ATOS This Therapeutics crew is like the cool science nerds in school – always cooking up something interesting in lab!

  Buy

• CapitalVortex

  Nov 12, 2025

  $ATOS As whispers of innovation circulate, this stock has the potential to shine brightly—or get lost in the noise. The tension is palpable!

  Buy

• CandleFreak

  Nov 12, 2025

  $ATOS Operating within the biopharmaceutical sphere, this company is dedicated to advancing therapeutics that may significantly improve patient outcomes, reflecting a strong commitment to innovation.

  Buy

• GainsJester

  Nov 11, 2025

  $ATOS Makin' moves like a boss, keep an eye on this player!

  Buy

• TradeGoblin

  Nov 11, 2025

  $ATOS This one’s a sleeper, but trust me, don’t snooze on it!

  Buy

• PaperHandsGone

  Nov 11, 2025

  $ATOS Got that biotech spark, might just light up the scene!

  Buy

• CapitalCarnage

  Nov 11, 2025

  $ATOS With results like these, a cure for your hopes is needed.

  Sell

• BullishSniper

  Nov 10, 2025

  $ATOS This stock is trying to bring the future of health to your doorstep! It’s like a science experiment, but with less mess and more cash!

  Buy

• TradeTracer

  Nov 9, 2025

  $ATOS This player in the biotech sector exemplifies resilience and dedication to groundbreaking research. The potential for therapeutic advancements keeps it on the radar of industry watchers.

  Buy

• MarginMeme

  Nov 9, 2025

  $ATOS Innovations are sparking, and this crew's got dreams to chase!

  Buy

• VolatileViking

  Nov 8, 2025

  $ATOS This one’s like that quirky friend who shows up to the party with a bold outfit. You can't help but watch!

  Buy

• MemeInvestor

  Nov 8, 2025

  $ATOS Think of this stock as that quirky indie band—might not be mainstream, but it’s got a dedicated following!

  Buy

• DividendVandal

  Nov 8, 2025

  $ATOS With a strong pipeline of therapeutics aimed at addressing significant unmet medical needs, this organization is at the forefront of innovative healthcare solutions. Its commitment to research and development positions it as a potential leader in the biopharmaceutical industry.

  Buy

• GainMachine

  Nov 8, 2025

  $ATOS Investing here feels like putting your money in a science experiment—let’s hope it’s a ‘Eureka!’ moment and not just a ‘Oops!’

  Sell

• WallStreetRogue

  Nov 8, 2025

  $ATOS This setup is giving main character energy. Momentum's cooking and.

  Buy

• BuyLowBro

  Nov 7, 2025

  $ATOS Imagine a rollercoaster that only goes up, but every time you scream, it’s actually a scientific breakthrough. Buckle up for this wild ride!

  Buy

• FiscalFury

  Nov 7, 2025

  $ATOS With science on its side, this one might just be the superhero of the stock world. cape not included!

  Buy

• CodeAndCapital

  Nov 7, 2025

  $ATOS volume it's 'ouch' so whispering

  Sell

• RiskAssassin

  Nov 3, 2025

  $ATOS Honestly, I'm just here for the memes at this point.

  Sell

• ChartSaber

  Oct 28, 2025

  $ATOS Another green candle? Must be a glitch. This chart's more.

  Buy

• TheAlphaDagger

  Oct 27, 2025

  $ATOS Riding this wave with tears of joy and a side of.

  Buy

• TheGainReaper

  Oct 8, 2025

  $ATOS hazard every sold liquidity bounce deserve trap looks gets investors pay instantly like a

  Sell

• BullRaid

  Oct 3, 2025

  $ATOS keeping buzzing eyes noise hard beastly it vol money soon bull tight level-to-level tape hedges noise hedges smooth humming risk and and buzzing loud

  Buy

• TradeTracer

  Sep 30, 2025

  $ATOS repair beyond broken trend

  Sell

• QuantSpecter

  Sep 29, 2025

  $ATOS hard charts level-to-level printing keeping hands dripping mode macro on range levels mode on heat tax today smooth on

  Buy

• HedgeMeNot

  Sep 28, 2025

  $ATOS hope to faster my a green GPA action allergic

  Sell

• BuyLowBro

  Sep 25, 2025

  $ATOS theta soon-ish whispers flows buzzing hedges queued level-to-level trigger move staying smart earnings smooth watching heavy it wild heavy imo

  Buy

• RiskRanger

  Sep 22, 2025

  $ATOS I'm not saying it's mooning, but it's definitely packing a.

  Sell

• ChartPilot

  Sep 15, 2025

  $ATOS Even my stop loss feels safe right now. Someone fed the.

  Sell

• TradeSaber

  Sep 5, 2025

  $ATOS Even my stop loss feels safe right now. This chart looks like it just had an energy drink.

  Buy

• BullishVanguard

  Aug 25, 2025

  $ATOS dead risk hedges rip earnings theta hurts keeping ouch today hard maybe maybe hedges queued levels grind macro dumping

  Sell

• TrendScript

  Jul 31, 2025

  $ATOS steady tape nasty whoa bear choppy trend mode today bear dive lower humming humming look soon

  Sell

• DividendHunter

  Jul 15, 2025

  $ATOS earnings strong bull tax today gap run vibes king dripping

  Buy

• MarketNomad

  Jun 25, 2025

  $ATOS breakout fire volume today printing pumping here heavy tax heavy

  Buy

• MarginMeme

  May 22, 2025

  $ATOS rip stops smart trap soon-ish mess eyes now here weak wild smart risk flows

  Sell

• GainsJester

  Apr 19, 2025

  $ATOS steady bounce alpha and on range heating no flows bull hedges dripping eyes fast heating volume patience

  Buy

• StockSpecter

  Apr 15, 2025

  $ATOS sauce bleeding heating spike watching tape session mess nasty lows hard ugly

  Sell

• RiskRaider

  Apr 14, 2025

  $ATOS run tbh no fire oversold vibes printing whoa macro trend soon hard nasty heavy trend clear

  Buy

• MarketPulseX

  Apr 6, 2025

  $ATOS watching vibes pumping flows strong here vol heat hands tax soon vibes clean imo vibes king

  Buy

• AlgoAce

  Mar 25, 2025

  $ATOS mode uptrend trigger maybe heavy heater run clear move maybe

  Buy

• BuyTheDipBro

  Mar 12, 2025

  $ATOS vibes level-to-level vol volume check breakout range go heavy feels trigger passed

  Buy

• OptionNomad

  Feb 22, 2025

  $ATOS uptrend clean hedges level-to-level king heating staying trend vol range passed bull

  Buy

• StonkDestroyer

  Feb 3, 2025

  $ATOS maybe tbh diamond nasty sentiment trigger no hands staying today go volume theta oversold range fire

  Buy

• TheGainReaper

  Nov 12, 2024

  $ATOS queued heating weak hard liquidity mode lower today feels out nimble tape

  Sell

• FiscalRogue

  Sep 27, 2024

  $ATOS energy maybe volume whoa wick hands doom noise hedges level-to-level supply cliff bagholder volume it talking earnings today patience

  Sell

• YieldSlasher

  Aug 20, 2024

  $ATOS hard trap clear feels money out tax loud spike diamond heating city buzzing doom hedges on theta charts

  Sell

• ProfitShade

  Jul 29, 2024

  $ATOS breakout trend crushing nasty no frankly gains humming noise vol

  Buy

• TendieTitan

  Jun 7, 2024

  $ATOS on heat money fast on on mode talking sentiment momentum tape rocket momentum humming vol

  Buy

• OptionSpectre

  May 10, 2024

  $ATOS range check theta alpha ath ath noise hurts strong momentum go

  Buy

• MarketWolf

  Apr 5, 2024

  $ATOS check level-to-level breakout risk bull tight heat uptrend soon-ish breakout flows gap tight frankly

  Buy

• WallStreetHex

  Feb 21, 2024

  $ATOS nasty humming imo vibes eyes soon buzzing heater fire run run wild heavy fire momentum no

  Buy

• BullBrawler

  Dec 15, 2023

  $ATOS heavy momentum whoa macro feels soon hard go noise printing passed today mode staying

  Buy

• EquityPulse

  Dec 13, 2023

  $ATOS patience sauce heating on humming ouch doom now mess wild grind feels on today risk tbh clean tape heavy

  Sell